All the major chemokine receptor-targeted therapeutic strategies for CTCL, including CCR4, CXCR4, CCR5, and CCR6 modulators, are summarized in Table 4. The gene discussed is CCR5; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.